Amsphere™ A3 is a next generation Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.
“The support provided by our global applications teams really helped make this happen,” said Hideaki Nomura, general manager of JSR Life Sciences’ Bioprocess Division. “Despite international supply chain disruptions affecting most global companies, we are in a position not only to maintain our commitments, but to expand our bioprocess purification materials to support more biologics companies in their pursuit of promising treatments for patients.”
The company is currently expanding on all fronts to facilitate increased manufacturing of biologics. Along with its first commercial launch, Amsphere™ A3 is currently being used in more than 95 clinical programs worldwide.
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience Inc., KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.